The three largest pharmacy benefit managers (PBMs) inflated the price of specialty generic drugs beyond their costs of ...
The Federal Trade Commission (FTC) on Tuesday released its second interim report on pharmacy benefit managers (PBM), saying ...
Major pharmacy-benefit managers generated $7.3 billion in markups on specialty drugs from pharmacies they are affiliated with ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
CVS Caremark, Express Scripts and OptumRx dramatically mark up specialty generic drugs to affiliated pharmacies, the Federal ...
Shocking revelations from a Federal Trade Commission, or FTC, investigation have exposed how three major prescription benefit managers, or PBMs, ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
Cigna (CI) and UnitedHealth (UNH) significantly marked up prices for specialty generic drugs over a six-year period.
CNBC's Bertha Coombs reports on the latest news from the FTC.
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
The FTC released a 60-page report Tuesday targeting the biggest three pharmacy benefit managers, claiming the companies hiked the prices of specialty drugs to generate $7.3 billion in revenue from ...
For the second time in less than a year, the FTC has released a highly critical report of pharmacy benefit managers, or PBMs.